View Post

Breast cancer drugs could help treat therapy-resistant lung cancers

In Clinical Trials by Barbara Jacoby

Source: PTI | London From: theweek.in A class of drugs used to treat certain breast cancers could help fight lung cancers A class of drugs used to treat certain breast cancers could help fight lung cancers that have become resistant to targeted therapies, according to a study conducted in mice. The study, published in the journal Cell Reports, found that …

View Post

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

In Clinical Trials by Barbara Jacoby

Source: PRNewswire From: biospace.com Subgroup analyses demonstrate consistent benefit in subgroups of patients with a more concerning prognosis such as those with liver metastases, PR-negative disease, high tumor grade, or shorter treatment-free interval Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical …

View Post

Sermonix Reports FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene

In Clinical Trials by Barbara Jacoby

From: streetinsider.com Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application, indicating that Sermonix may proceed directly to a Phase 2 clinical study in the personalized medicine arena involving its lead investigational drug, …

View Post

Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Alex Keown From: biospace.com Amgen provided $2 million to the nonprofit Lazarex Cancer Foundation to support an effort to improve minority patient access to the potentially life-saving drugs in oncology clinical trials. Amgen’s contribution will go to Lazarex’s IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable …

View Post

DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

In Clinical Trials by Barbara Jacoby

Source: DNAtrix From: prnewswire.com DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L). The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440, administered by Alcyone’s Microtip Cannula at the time of biopsy, to patients with recurrent glioblastoma for whom …

View Post

Legislature passes bill to improve access to cancer clinical trials

In Clinical Trials by Barbara Jacoby

From: dailylocal.com WEST CHESTER—A new law designed to improve access to clinical trials for Pennsylvanians battling cancer is heading to the governor’s desk, state Senator Andy Dinniman said. House Bill 126 unanimously passed the Pennsylvania Senate this week after receiving unanimous approval in the House earlier this year. The bill was amended to include language from Dinniman’s Senate Bill 576, …

View Post

NCI Supports Precision Medicine with Updated Clinical Trial Criteria

In Clinical Trials by Barbara Jacoby

By: Jessica Kent From: healthitanalytics.com The updated clinical trial criteria will broaden eligibility and participation in cancer trials, potentially leading to precision medicine breakthroughs. The National Cancer Institute (NCI) has revised its clinical trial protocol template to expand eligibility criteria for cancer clinical trials. The updated criteria will allow patients with certain health conditions to participate in NCI-funded trials, as …

View Post

New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors

In Clinical Trials by Barbara Jacoby

From: cancerresearch.org 2,250 clinical trials are evaluating PD-1/L1 immune checkpoint inhibitors, an increase of 748 trials over the past year 1,716 trials are assessing regimens that combine PD-1/L1 immune checkpoints with other cancer therapies 240 drug targets are being evaluated in the current landscape, 75 more targets compared to a year ago Over 380,000 patient volunteers are required to fill …

View Post

SWOG shares trio of studies at San Antonio breast cancer symposium

In Clinical Trials by Barbara Jacoby

From: eurekalert.org SWOG Cancer Research Network members will share the results of three studies at the San Antonio Breast Cancer Symposium, an international gathering of breast cancer physicians and researchers that starts today, with an estimated 7,500 attendees expected from more than 90 countries. SWOG is an international cancer clinical trials network funded by the National Cancer Institute (NCI), part …